Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting.

The oral presentation describes the unique library of APC nanobodies and its potential as a source for novel treatments of diseases including trauma, hemophilia, ischemia and sepsis.

SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and its adjacent parts, has published data from preclinical studies on a novel library of llama-derived antibodies (nanobodies) targeting APC exosites. An oral presentation titled “Selective Modulation of Activated Protein C Activity Using a Library of Exosite-Specific Nanobodies” will be presented at the American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022.

Coagulant Therapeutics Corporation is a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and its adjacent parts.  (PRNewsfoto/Coagulant Therapeutics Corporation)

“This library of nanobodies not only offers potential treatments for acute bleeding conditions, such as trauma and hemorrhagic stroke, it also provides the opportunity to identify possible treatments in indications outside of acute bleeding where APC plays an important role, such as hemophilia and sepsis,” He said. Terry Hermiston, Ph.D., Founder and CEO of Coagulant Therapeutics. dr. Hermiston noted that the different mechanisms of action between the APC-targeting molecules and the company’s lead molecule, CT-001, an engineered highly potent, rapidly clearing FVIIa molecule, suggest that these molecules may actually complement each other in the clinic. “We are excited to explore their potential as adjunctive or synergistic agents in the treatment of acute bleeding.”

Data presented by Dr. sc. Derek Sim, Chief Scientific Officer for Coagulant Therapy, described new llama-derived nanobodies on the exosite of activated protein C (APC) that affect anticoagulation, histone cleavage, and receptor-mediated cleavage activities of APC. The characterization resulted in 13 new activity profiles that can be used to regulate specific APC functions for therapeutic purposes.

“APC differs from the parent protein C (PC) molecule in that it lacks 12 amino acids. We hoped to exploit the unique properties of the nanobody to generate antibodies that selectively inhibit some of the functions associated with APC,” reported Dr. Sim ” and we are very pleased to report the number and surprising variety of APC-specific nanobodies, exemplified by LP 11, whose profile of hemostasis activity and stimulation of cytoprotection makes it an attractive candidate for the treatment of hemophilia and trauma.”

In addition to an oral presentation on the APC library, Coagulant presented a poster on their lead molecule, CT-001.

Abstract title: CT-001, a rapid clearance factor VIIa, provides prohemostatic activity to reduce blood loss in coagulopathic conditions induced by activated protein C

Abstract number: 2458

Session name: 321. Coagulation and fibrinolysis: basic and translational: poster II

Session date: Sunday, December 11, 2022

Presentation time: 6:00pm-8:00pm CST/7:00am-9:00pm EST

Leader: Dr. Derek Sim

Abstract: These data, which were presented by Dr. sc. Derek Sim, Chief Scientific Officer of Coagulant Therapy, suggests that an FVIIa molecule engineered to be both safer and more active than recombinant FVIIa (rFVIIa) may be an effective treatment for acute bleeding, including bleeding with coagulopathy, broadly defined as a disorder of hemostasis that results in impaired clot formation. CT-001 is being developed as a new treatment for severe postpartum hemorrhage, a growing problem and a significant factor in maternal morbidity and mortality not only in the US but globally. These studies support its potential wider use in coagulopathic situations such as trauma.

About CT-001

CT-001 is an engineered version of FVIIa designed to address the limitations of recombinant FVIIa (rFVIIa), approved for use in patients with hemophilia A and B with inhibitors, congenital FVII deficiency, and Glanzmann thrombasthenia with resistance to platelet transfusions, but not approved in the US- u for use in acute bleeding situations such as trauma, traumatic brain injury, intracranial hemorrhage, or severe postpartum hemorrhage. To improve safety and address the risk of unwanted clotting with rFVIIa, CT-001 is designed to be rapidly cleared from the blood. This feature reduces the time an individual is exposed to procoagulant activity, which reduces the risk of thromboembolic events. To improve efficacy, while compensating for the rapid clearance of CT-001 from the blood, the molecule was also engineered to target the site of bleeding more efficiently and effectively than rFVIIa, resulting in increased activity. CT-001 was originally developed by Dr. Hermiston while he was Vice President of Biology at Bayer AG and was later acquired by the company. CT-001 is currently under investigation for the treatment of severe postpartum hemorrhage.

About the APC Antibody Program

APC is a pleiotropic enzyme that has been identified as a target in the treatment of a variety of disease indications including trauma, hemophilia, ischemia, and sepsis. Coagulant Therapeutics Corporation has initiated a research program to identify therapeutic antibodies targeting APC, using the unique features of llama antibodies (nanobodies) to perform novel nanobodies on protein exosites. The nanobody library has a variety of different antibodies to different epitopes and, more importantly, has created a lead that is being studied for the treatment of trauma, namely hemophilia. Because these nanoparticles have a different target and mechanism of action than CT-001, it is expected that they may be independent treatments with the potential for additive or synergistic effects on CT-001 in the setting of acute bleeding.

About Coagulant Therapeutics Corporation

Coagulant Therapeutics is a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and its adjacent parts. The company’s lead product candidate, CT-001, is a next-generation factor VIIa designed for increased efficacy and safety in the setting of acute bleeding. Coagulant is also developing additional APC-targeted therapy for the treatment of acute bleeding and other diseases associated with the coagulation cascade. Founded in 2019, the company is located in Berkeley, California.

Media contact:

Eliza Schleifstein
[email protected]

Cision View original content for multimedia download: -at-2022-american-society-of-hematology-ash-annual-meeting-301699793.html

SOURCE Coagulant Therapeutics Corporation

Leave a Comment

Your email address will not be published. Required fields are marked *